Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727631 | 0.91 | ADORA2A (0.53) | ADORA2AADORA1ADORA3ADRA2AADRA2B | |
| SCHEMBL6635797 | 0.90 | ADORA2A (0.49) | ADORA2AADORA1ADORA3ADRA2AADRA2B | |
| SCHEMBL6632380 | 0.88 | ADRA2A (0.46) | ADORA2AADORA1ADORA3ADRA2AADRA2B | |
| SCHEMBL6632462 | 0.87 | ADORA2A (0.49) | ADORA2AADORA1ADORA3ADRA2AADRA2B | |
| SCHEMBL6632408 | 0.85 | ADORA2A (0.52) | ADORA2AADORA1ADORA3ADRA2AADRA2B | |
| SCHEMBL6634776 | 0.85 | ADORA2A (0.54) | ADORA2AADORA1ADORA3ADRA2AADRA2B | |
| SCHEMBL6633375 | 0.85 | ADORA2A (0.44) | ADORA2AADORA1ADORA3ADRA2AADRA2B | |
| SCHEMBL6632003 | 0.85 | ADORA2A (0.49) | ADORA2AADORA1ADRA2AADRA2BADRA2C | |
| SCHEMBL6636517 | 0.84 | ADRA2A (0.53) | ADORA2AADORA1ADORA3ADRA2AADRA2B | |
| SCHEMBL6631101 | 0.82 | ADRA2A (0.45) | ADORA2AADORA1ADORA3ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430898-A1 | RECEPTOR ANTAGONIST | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040110826-A1 | Receptor Antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110826-A1 | Receptor Antagonists | ADRA2C, OPRL1, ADRB1 | ADORA2A 89/4885ADORA1 129/4885ADORA3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.